The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis
Open accessAbstract
BACKGROUND: Small intestinal bacterial overgrowth may contribute to the development of non-alcoholic steatohepatitis, perhaps by increasing intestinal permeability and promoting the absorption of endotoxin or other enteric bacterial products. AIMS: To investigate the prevalence of small intestinal bacterial overgrowth, increased intestinal permeability, elevated endotoxin, and tumour necrosis factor α (TNF-α) levels in patients with non-alcoholic steatohepatitis and in control subjects. PATIENTS AND METHODS: Twenty two patients with non-alcoholic steatohepatitis and 23 control subjects were studied. Small intestinal bacterial overgrowth was assessed by a combined 14 C- d -xylose and lactulose breath test. Intestinal permeability was assessed by a dual lactulose-rhamnose sugar test. Serum endotoxin levels were determined using the limulus amoebocyte lysate assay and TNF-α levels using an ELISA. RESULTS: Small intestinal bacterial overgrowth was present in 50% of patients with non-alcoholic steatosis and 22% of control subjects (p=0.048). Mean TNF-α levels in non-alcoholic steatohepatitis patients and control subjects were 14.2 and 7.5 pg/ml, respectively (p=0.001). Intestinal permeability and serum endotoxin levels were similar in the two groups. CONCLUSIONS: Patients with non-alcoholic steatohepatitis have a higher prevalence of small intestinal bacterial overgrowth, as assessed by the 14 C- d -xylose-lactulose breath test, and higher TNF-α levels in comparison with control subjects. This is not accompanied by increased intestinal permeability or elevated endotoxin levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yang, S. Q., Lin, H. Z., Lane, M. D., Clemens, M., & Diehl, A. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2557 · Cited by 810
Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing
Mohler, K. M., Sleath, P. R., Fitzner, J. N., Cerretti, D. P., Alderson, M., Kerwar, S. S., Torranee, D. S., Otten-Evans, C., Greenstreet, T., Weerawarna, K., et al. (1994) · Nature · doi:10.1038/370218a0 · Cited by 588
AGA Technical Review on the Evaluation and Management of Chronic Diarrhea☆
FINE, K., & SCHILLER, L. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70513-5 · Cited by 383
Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.
Ashkenazi, A., Marsters, S. A., Capon, D. J., Chamow, S. M., Figari, I. S., Pennica, D., Goeddel, D. V., Palladino, M. A., & Smith, D. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10535 · Cited by 275
Non‐alcoholic steatohepatitis: another disease of affluence
James, *., & Day, C. (1999) · The Lancet · doi:10.1016/s0140-6736(99)00163-4 · Cited by 271
Drenick, E. J., Fisler, J., & Johnson, D. (1982) · Gastroenterology · doi:10.1016/s0016-5085(82)80403-4 · Cited by 226
Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth
Lichtman, S. N., Sartor, R. B., Keku, J., & Schwab, J. H. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90833-m · Cited by 209
Lichtman, S. N., Keku, J., Schwab, J. H., & Sartor, R. B. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90224-9 · Cited by 175
RECURRENCE OF NONALCOHOLIC STEATOHEPATITIS FOLLOWING LIVER TRANSPLANTATION1
Kim, W. R., Poterucha, J. J., Porayko, M. K., Dickson, E. R., Steers, J. L., & Wiesner, R. H. (1996) · Transplantation · doi:10.1097/00007890-199612270-00021 · Cited by 168
Tarao, K., So, K., Moroi, T., Ikeuchi, T., Suyama, T. L., Endo, O., & Fukushima, K. (1977) · Gastroenterology · doi:10.1016/s0016-5085(19)32137-7 · Cited by 143
Cited by
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Nonalcoholic fatty liver disease
Adams, L. A. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.045232 · Cited by 1,610
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Gabrieli, M. L., Perotti, G., et al. (2009) · Hepatology · doi:10.1002/hep.22848 · Cited by 1,434
“9) 0 Villi ZO-1 nuclei (%) 7 (4-12) 1 (0-3) 0.”
InfluentialRegulation of Tight Junction Permeability by Intestinal Bacteria and Dietary Components1,2
Ulluwishewa, D., Anderson, R. C., McNabb, W. C., Moughan, P. J., Wells, J. M., & Roy, N. C. (2011) · The Journal of Nutrition · doi:10.3945/jn.110.135657 · Cited by 1,177
The role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020
Interactions Between the Intestinal Microbiome and Liver Diseases
Schnabl, B., & Brenner, D. A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.020 · Cited by 971
Beyond insulin resistance in NASH: TNF-α or adiponectin?
Hui, J. M., Hodge, A., Farrell, G. C., Kench, J. G., Kriketos, A., & George, J. (2004) · Hepatology · doi:10.1002/hep.20280 · Cited by 942
Li, Z., Yang, S., Lin, H., Huang, J., Watkins, P. A., Moser, A. B., DeSimone, C., Song, X.-Y., & Diehl, A. M. (2003) · Hepatology · doi:10.1053/jhep.2003.50048 · Cited by 930
Cani, P. D., Osto, M., Geurts, L., & Everard, A. (2012) · Gut Microbes · doi:10.4161/gmic.19625 · Cited by 864
Brun, P., Castagliuolo, I., Leo, V. D., Buda, A., Pinzani, M., Palù, G., & Martines, D. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00024.2006 · Cited by 864
Role of Kupffer cells in host defense and liver disease
Bilzer, M., Roggel, F., & Gerbes, A. L. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01342.x · Cited by 856
Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis
Cai, J., Sun, L., & Gonzalez, F. J. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.02.004 · Cited by 843
Intestinal microbiota in patients with nonalcoholic fatty liver disease
Mouzaki, M., Comelli, E. M., Arendt, B. M., Bonengel, J., Fung, S. K., Fischer, S. E., McGilvray, I. D., & Allard, J. P. (2013) · Hepatology · doi:10.1002/hep.26319 · Cited by 749
Pathogenesis of non-alcoholic fatty liver disease
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010) · QJM · doi:10.1093/qjmed/hcp158 · Cited by 741
Del Chierico, F., Nobili, V., Vernocchi, P., Russo, A., De Stefanis, C., Gnani, D., Furlanello, C., Zandonà, A., Paci, P., Capuani, G., et al. (2017) · Hepatology · doi:10.1002/hep.28572 · Cited by 696
“Thus, quantitative and qualitative variations in the bacteria that compose the gut microbiota may actively contribute to the pathogenesis of several liver diseases, including nonalcoholic fatty liver disease (NAFLD), alcoholic steatohepatitis, and cirrhosis.((2-7)) NAFLD is one of the most common causes of chronic liv…”
BackgroundRivera, C. A., Adegboyega, P., van Rooijen, N., Tagalicud, A., Allman, M., & Wallace, M. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.019 · Cited by 693
“Gastroenterology 1979 Apr;76(4):710–719.”
BackgroundInfluentialCrespo, J., Cayón, A., Fernández-Gil, P., Hernández-Guerra, M., Mayorga, M., Domínguez-Díez, A., Fernández-Escalante, J. C., & Pons-Romero, F. (2001) · Hepatology · doi:10.1053/jhep.2001.29628 · Cited by 693
Paracellular permeability and tight junction regulation in gut health and disease
Horowitz, A., Chanez-Paredes, S. D., Haest, X., & Turner, J. R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00766-3 · Cited by 687
Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome
Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P., & Loria, P. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.09.020 · Cited by 685
Small intestinal bacterial overgrowth syndrome
Bures, J. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i24.2978 · Cited by 620
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611
Causes and Metabolic Consequences of Fatty Liver
Stefan, N., Kantartzis, K., & Häring, H.-U. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0009 · Cited by 532
Gut microbiome and liver diseases
Tilg, H., Cani, P. D., & Mayer, E. A. (2016) · Gut · doi:10.1136/gutjnl-2016-312729 · Cited by 525
Tolman, K. G., Fonseca, V., Dalpiaz, A., & Tan, M. H. (2007) · Diabetes Care · doi:10.2337/dc06-1539 · Cited by 525
Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: Role of endotoxin
Bergheim, I., Weber, S., Vos, M., Krämer, S., Volynets, V., Kaserouni, S., McClain, C. J., & Bischoff, S. C. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.035 · Cited by 522
Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients
VIDELA, L. A., RODRIGO, R., ORELLANA, M., FERNANDEZ, V., TAPIA, G., QUIÑONES, L., VARELA, N., CONTRERAS, J., LAZARTE, R., CSENDES, A., et al. (2004) · Clinical Science · doi:10.1042/cs20030285 · Cited by 515
Cytokines and Nash: A Pilot Study of the Effects of Lifestyle Modification and Vitamin E
Kugelmas, M., Hill, D. B., Vivian, B., Marsano, L., & McClain, C. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50316 · Cited by 504
The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)
Safari, Z., & Gérard, P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03011-w · Cited by 502
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Fuchs, C. D., & Trauner, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00566-7 · Cited by 490
Fasano, A., & Shea-Donohue, T. (2005) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0259 · Cited by 484
Manco, M., Putignani, L., & Bottazzo, G. F. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0030 · Cited by 483
Fernandez, F. G., Ritter, J., Goodwin, J. W., Linehan, D. C., Hawkins, W. G., & Strasberg, S. M. (2005) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2005.01.024 · Cited by 465
The role of the gut microbiota in nonalcoholic fatty liver disease
Abu-Shanab, A., & Quigley, E. M. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.172 · Cited by 457
Bifidobacterium longum with Fructo-Oligosaccharides in Patients with Non Alcoholic Steatohepatitis
Malaguarnera, M., Vacante, M., Antic, T., Giordano, M., Chisari, G., Acquaviva, R., Mastrojeni, S., Malaguarnera, G., Mistretta, A., Li Volti, G., et al. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1887-4 · Cited by 455
Gut Microbiota and Inflammation
Hakansson, A., & Molin, G. (2011) · Nutrients · doi:10.3390/nu3060637 · Cited by 455
Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases
Loguercio, C., Federico, A., Tuccillo, C., Terracciano, F., D'Auria, M. V., De Simone, C., & Blanco, C. D. V. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000165671.25272.0f · Cited by 449
Pathogenesis of steatohepatitis
Day, C. P. (2002) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2002.0333 · Cited by 431
Role of the gut microbiota in type 2 diabetes and related diseases
Yang, G., Wei, J., Liu, P., Zhang, Q., Tian, Y., Hou, G., Meng, L., Xin, Y., & Jiang, X. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154712 · Cited by 418
Thuy, S., Ladurner, R., Volynets, V., Wagner, S., Strahl, S., Königsrainer, A., Maier, K.-P., Bischoff, S. C., & Bergheim, I. (2008) · The Journal of Nutrition · doi:10.1093/jn/138.8.1452 · Cited by 412
Kwok, R., Tse, Y. ‐., Wong, G. L. ‐., Ha, Y., Lee, A. U., Ngu, M. C., Chan, H. L. ‐., & Wong, V. W. ‐. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12569 · Cited by 405
NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications
Farrell, G. C., Rooyen, D. V., Gan, L., & Chitturi, S. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.2.149 · Cited by 398
Elevated endotoxin levels in non-alcoholic fatty liver disease
Harte, A. L., da Silva, N. F., Creely, S. J., McGee, K. C., Billyard, T., Youssef-Elabd, E. M., Tripathi, G., Ashour, E., Abdalla, M. S., Sharada, H. M., et al. (2010) · Journal of Inflammation · doi:10.1186/1476-9255-7-15 · Cited by 390
Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease
Mouzaki, M., Wang, A. Y., Bandsma, R., Comelli, E. M., Arendt, B. M., Zhang, L., Fung, S., Fischer, S. E., McGilvray, I. G., & Allard, J. P. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151829 · Cited by 385
Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis
Anderson, N., & Borlak, J. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.00001 · Cited by 385
Thirty Years of Lactobacillus rhamnosus GG: A Review
Capurso, L. (2019) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001170 · Cited by 381
Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation
Peverill, W., Powell, L., & Skoien, R. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15058591 · Cited by 376
The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases
Soares, J.-B., Pimentel-Nunes, P., Roncon-Albuquerque, R., & Leite-Moreira, A. (2010) · Hepatology International · doi:10.1007/s12072-010-9219-x · Cited by 367
Intestinal Permeability Defects: Is It Time to Treat?
Odenwald, M. A., & Turner, J. R. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.07.001 · Cited by 366
Chitturi, S., Farrell, G., Frost, L., Kriketos, A., Lin, R., Liddle, C., Samarasinghe, D., & George, J. (2002) · Hepatology · doi:10.1053/jhep.2002.34738 · Cited by 362
Microbiome-modulated metabolites at the interface of host immunity
Blacher, E., Levy, M., Tatirovsky, E., & Elinav, E. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601247 · Cited by 354
Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis
Ma, Y.-Y. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i40.6911 · Cited by 352
Effects of Lactobacillus rhamnosus Strain GG in Pediatric Obesity‐related Liver Disease
Vajro, P., Mandato, C., Licenziati, M. R., Franzese, A., Vitale, D. F., Lenta, S., Caropreso, M., Vallone, G., & Meli, R. (2011) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31821f9b85 · Cited by 341
Rahman, K., Desai, C., Iyer, S. S., Thorn, N. E., Kumar, P., Liu, Y., Smith, T., Neish, A. S., Li, H., Tan, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.06.022 · Cited by 334
Small Intestinal Bacterial Overgrowth: Roles of Antibiotics, Prebiotics, and Probiotics
Quigley, E. M. M., & Quera, R. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.046 · Cited by 329
Gut–liver axis, nutrition, and non-alcoholic fatty liver disease
Kirpich, I. A., Marsano, L. S., & McClain, C. J. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.06.023 · Cited by 327
du Plessis, J., van Pelt, J., Korf, H., Mathieu, C., van der Schueren, B., Lannoo, M., Oyen, T., Topal, B., Fetter, G., Nayler, S., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.044 · Cited by 325
Gäbele, E., Dostert, K., Hofmann, C., Wiest, R., Schölmerich, J., Hellerbrand, C., & Obermeier, F. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.035 · Cited by 324
Recent concepts in non‐alcoholic fatty liver disease
Adams, L. A., & Angulo, P. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01748.x · Cited by 324
Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease
Fouts, D. E., Torralba, M., Nelson, K. E., Brenner, D. A., & Schnabl, B. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.019 · Cited by 311
Emerging roles of bile acids in mucosal immunity and inflammation
Chen, M. L., Takeda, K., & Sundrud, M. S. (2019) · Mucosal Immunology · doi:10.1038/s41385-019-0162-4 · Cited by 298
Management of the critically ill patient with cirrhosis: A multidisciplinary perspective
Nadim, M. K., Durand, F., Kellum, J. A., Levitsky, J., O’Leary, J. G., Karvellas, C. J., Bajaj, J. S., Davenport, A., Jalan, R., Angeli, P., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.019 · Cited by 297
Collins, E. J., Bowyer, C., Tsouza, A., & Chopra, M. (2022) · Biology · doi:10.3390/biology11020239 · Cited by 293
Nonalcoholic Fatty Liver Disease
Adams, L. A., & Lindor, K. D. (2007) · Annals of Epidemiology · doi:10.1016/j.annepidem.2007.05.013 · Cited by 289
Chakaroun, R., Massier, L., & Kovacs, P. (2020) · Nutrients · doi:10.3390/nu12041082 · Cited by 289
dela Peña, A., Leclercq, I., Field, J., George, J., Jones, B., & Farrell, G. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.09.004 · Cited by 287
Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability
Luther, J., Garber, J. J., Khalili, H., Dave, M., Bale, S. S., Jindal, R., Motola, D. L., Luther, S., Bohr, S., Jeoung, S. W., et al. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.01.001 · Cited by 286
Spengler, E. K., & Loomba, R. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.06.013 · Cited by 284
Qureshi, K. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i26.3540 · Cited by 283
Gut Microbiota Is a Key Modulator of Insulin Resistance in TLR 2 Knockout Mice
Caricilli, A. M., Picardi, P. K., de Abreu, L. L., Ueno, M., Prada, P. O., Ropelle, E. R., Hirabara, S. M., Castoldi, Â., Vieira, P., Camara, N. O. S., et al. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001212 · Cited by 282
RetractedIntestinal Permeation and Gastrointestinal Disease
DeMeo, M. T., Mutlu, E. A., Keshavarzian, A., & Tobin, M. C. (2002) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200204000-00003 · Cited by 272
Qiu, Y.-Y., Zhang, J., Zeng, F.-Y., & Zhu, Y. Z. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106786 · Cited by 271
Volynets, V., Küper, M. A., Strahl, S., Maier, I. B., Spruss, A., Wagnerberger, S., Königsrainer, A., Bischoff, S. C., & Bergheim, I. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2112-9 · Cited by 268
Guerra Ruiz, A., Casafont, F., Crespo, J., Cayón, A., Mayorga, M., Estebanez, A., Fernadez-Escalante, J. C., & Pons-Romero, F. (2007) · Obesity Surgery · doi:10.1007/s11695-007-9243-7 · Cited by 269
Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease
Torres, D. M., Williams, C. D., & Harrison, S. A. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.03.011 · Cited by 268
Pathogenesis and management issues for non-alcoholic fatty liver disease
Duvnjak, M. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i34.4539 · Cited by 264
Dietary fat, bile acid metabolism and colorectal cancer
Ocvirk, S., & O’Keefe, S. J. D. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.10.003 · Cited by 262
Non-alcoholic fatty liver and the gut microbiota
Bashiardes, S., Shapiro, H., Rozin, S., Shibolet, O., & Elinav, E. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.003 · Cited by 241
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis
Cai, J., Zhang, X., & Li, H. (2019) · Hepatology · doi:10.1002/hep.30506 · Cited by 207
“noted the strong connection between intestinal bacterial overgrowth and a high prevalence of NASH in humans.(21) At that time, studies also began to explore the subcellular innate signaling molecules and pathways involved in NASH, such as Toll-like receptors (TLRs), c-Jun N-terminal kinase ( JNK), and the inhibitor of…”
BackgroundCommensal microbiota is hepatoprotective and prevents liver fibrosis in mice
Mazagova, M., Wang, L., Anfora, A. T., Wissmueller, M., Lesley, S. A., Miyamoto, Y., Eckmann, L., Dhungana, S., Pathmasiri, W., Sumner, S., et al. (2015) · The FASEB Journal · doi:10.1096/fj.14-259515 · Cited by 199
Gut microbiota and probiotics in chronic liver diseases
Cesaro, C., Tiso, A., Del Prete, A., Cariello, R., Tuccillo, C., Cotticelli, G., del Vecchio Blanco, C., & Loguercio, C. (2011) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.10.015 · Cited by 182
Sahai, A., Malladi, P., Melin-Aldana, H., Green, R. M., & Whitington, P. F. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00002.2004 · Cited by 181
“Patients with NASH exhibit elevated serum and hepatic levels of TNF- , and an anti-TNF- antibody has been shown to reduce inflammation in animal models of NAFLD (6, 18, 21, 48).”
BackgroundNon‐alcoholic steatohepatitis (NASH): where are we now and where are we going?
Day, C. P. (2002) · Gut · doi:10.1136/gut.50.5.585 · Cited by 181
Pathophysiology of NASH: perspectives for a targeted treatment
Marra, F., & Lotersztajn, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990344 · Cited by 163
Spruss, A., & Bergheim, I. (2009) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.05.006 · Cited by 162
Furusho, H., Miyauchi, M., Hyogo, H., Inubushi, T., Ao, M., Ouhara, K., Hisatune, J., Kurihara, H., Sugai, M., Hayes, C. N., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-012-0738-1 · Cited by 157
Kudo, H., Takahara, T., Yata, Y., Kawai, K., Zhang, W., & Sugiyama, T. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.02.032 · Cited by 152
De Munck, T. J. I., Xu, P., Verwijs, H. J. A., Masclee, A. A. M., Jonkers, D., Verbeek, J., & Koek, G. H. (2020) · Liver International · doi:10.1111/liv.14696 · Cited by 145
“…USA21 Adult 16 NAFLD - 6 NAFL - 10 NASH Biopsyc 12 HC BMI < 25 L/M (5h) + Sucralose (24h) L/M = NAFL/NASH/HC (P not given) Sucralose = NAFL/NASH/HC (P not given) Wigg et al 2001, Australia38 Adult 18 NASH Biopsyd 16 HC liver function L/R (5h) L/R NASH = IP HC (P = .37) Abbreviations: NP, Not…”
Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease
Reilly, N. R., Lebwohl, B., Hultcrantz, R., Green, P. H. R., & Ludvigsson, J. F. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.013 · Cited by 110
Searching for coeliac disease in patients with non-alcoholic fatty liver disease
Bardella, M. T., Valenti, L., Pagliari, C., Peracchi, M., Farè, M., Fracanzani, A. L., & Fargion, S. (2004) · Digestive and Liver Disease · doi:10.1016/j.dld.2004.01.012 · Cited by 92
Rai, R. P., Liu, Y., Iyer, S. S., Liu, S., Gupta, B., Desai, C., Kumar, P., Smith, T., Singhi, A. D., Nusrat, A., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.05.047 · Cited by 86
Gut microbiota, fatty liver disease, and hepatocellular carcinoma
Chu, H., Williams, B., & Schnabl, B. (2018) · Liver Research · doi:10.1016/j.livres.2017.11.005 · Cited by 84
Schiffrin, E. J., Parlesak, A., Bode, C., Christian Bode, J., van't Hof, M. A., Grathwohl, D., & Guigoz, Y. (2008) · British Journal of Nutrition · doi:10.1017/s0007114508055591 · Cited by 74
The immune landscape in nonalcoholic steatohepatitis
Narayanan, S., Surette, F. A., & Hahn, Y. S. (2016) · Immune Network · doi:10.4110/in.2016.16.3.147 · Cited by 64
Quigley, E. M. M. (2007) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2007.07.012 · Cited by 67
Visschers, R. G. J., Luyer, M. D., Schaap, F. G., Olde Damink, S. W. M., & Soeters, P. B. (2013) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32836410a4 · Cited by 60
Miyake, T., Abe, M., Tokumoto, Y., Hirooka, M., Furukawa, S., Kumagi, T., Hamada, M., Kawasaki, K., Tada, F., Ueda, T., et al. (2013) · Hepatology International · doi:10.1007/s12072-012-9345-8 · Cited by 59
Reversal of high-fat diet-induced hepatic steatosis by n-3 LCPUFA: Role of PPAR-α and SREBP-1c
Dossi, C. G., Tapia, G. S., Espinosa, A., Videla, L. A., & D'Espessailles, A. (2014) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2014.04.011 · Cited by 51
The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC
Wu, Q., Yang, Y., Lin, S., Geller, D. A., & Yan, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1569915 · Cited by 32
Metadata
- Authors
- Wigg, A. J., Roberts-Thomson, I. C., Dymock, R. B., McCarthy, P. J., Grose, R. H., & Cummins, A. G.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2001-02-01
- Volume
- 48
- Issue
- 2
- Pages
- 206-211
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2141158324
- Cited by
- 840
- References
- 17
- FWCI
- 13.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.